SCHEMBL4297486

SCHEMBL4297486

Cc1nc(O)cc(-c2ccccc2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.51
MAPT P10636 7/20 0.50
TP53 P04637 4/20 0.50
LMNA P02545 2/20 0.50
POLB P06746 2/20 0.50
GAA P10253 1/20 0.49
TSHR P16473 2/20 0.49
HSD17B10 Q99714 1/20 0.49
MEN1 O00255 5/20 0.48
NTSR1 P30989 1/20 0.48
ALDH1A1 P00352 3/20 0.47
KDM4E B2RXH2 2/20 0.47
PKM P14618 1/20 0.47
RAB9A P51151 1/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
TDP1 Q9NUW8 2/20 0.46
HPGD P15428 2/20 0.46
ATM Q13315 1/20 0.46
ADORA1 P30542 2/20 0.45
ADORA2A P29274 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10039374 0.85 KMT2A (0.60) KMT2AMAPTTP53LMNAPOLB
SCHEMBL10967059 0.84 MAPT (0.46) KMT2AMAPTTP53LMNAPOLB
SCHEMBL17286932 0.81 KMT2A (0.60) KMT2AMAPTTP53LMNAPOLB
SCHEMBL16353106 0.81 KMT2A (0.60) KMT2AMAPTTP53LMNAPOLB
SCHEMBL5420904 0.81 ADORA3 (0.43) KMT2AMEN1ALDH1A1KDM4ERAB9A
SCHEMBL16376438 0.80 KMT2A (0.57) KMT2AMAPTTP53LMNAPOLB
SCHEMBL3307656 0.79 MEN1 (0.68) KMT2AMAPTLMNAMEN1NTSR1
SCHEMBL3451123 0.79 MEN1 (0.52) KMT2AMAPTLMNAPOLBTSHR
SCHEMBL14970094 0.79 TSHR (0.56) KMT2AMAPTTP53LMNAPOLB
SCHEMBL9013563 0.78 DYRK1A (0.50) KMT2AMAPTTP53POLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295180-A1 PROTEIN DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-21 US disclosed
US-20090280133-A1 PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF MYRIAD GENETICS, INCORPORATED (US) 2009-11-12 US disclosed
US-20090280133-A1 PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF MYRIAD GENETICS, INCORPORATED (US) 2009-11-12 US disclosed
US-20090280133-A1 PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF MYRIAD GENETICS, INCORPORATED (US) 2009-11-12 US disclosed
WO-2008061112-A9 PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF MYRIAD GENETICS INC (US) 2008-09-18 WO disclosed
WO-2008061112-A9 PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF MYRIAD GENETICS INC (US) 2008-09-18 WO disclosed
WO-2008061112-A2 PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF MYRIAD GENETICS, INC. (US) 2008-05-22 WO disclosed
WO-2008061112-A2 PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF MYRIAD GENETICS, INC. (US) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090280133-A1 PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF MKI67, CCNI, CCNA1 KMT2A 4400/4885MAPT 3821/4885TP53 45/4885
US-20230295180-A1 PROTEIN DEGRADERS AND USES THEREOF MDM2, CUL1, PSMG3 KMT2A 1723/4885MAPT 489/4885TP53 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.